Medical Device Sales Salary Guide 2026: What Companies Need to Pay to Compete

I had a conversation with a VP of Sales at a mid-size orthopedic company in February that stuck with me. He'd just lost a candidate.

"We offered her $92K base with 40% variable. She turned us down for Stryker."

"What did Stryker offer?"

"$105K base, same variable structure, plus RSUs."

"So you lost her over $13K in base."

He paused. "We lost her over $13K and the fact that Stryker is Stryker. She told our recruiter she would have taken less from Stryker than she accepted. We weren't even in the conversation."

That last part is what I keep thinking about. It wasn't just the money. It was what the money communicated. A below-market offer signals something to a candidate, and whatever it signals, it isn't good.

Medical Device Sales Compensation by Specialty (2026)

Title: Medical Device Sales Compensation by Specialty (2026)

Based on compensation data gathered from roughly twenty reps, recruiters, and hiring managers over the past year. Directional, not exhaustive.

Orthopedics Still Pays the Most (But It's Complicated)

Orthopedic device sales has been the highest-paying corner of the medical device world for as long as I've been around. That's still true in 2026, but the details are worth understanding because "orthopedic sales" covers a pretty wide range of realities.

The rep at $300K total comp isn't three times better than the rep at $150K. She's been in her territory for seven years and has surgeon relationships that took that long to build. I asked her once if she'd ever leave and she looked at me like I'd suggested something obscene.

One thing I've noticed shifting: the conversation around case coverage. Orthopedic reps, particularly in joints and spine, are often expected in the OR at 6am. That used to be accepted as part of the deal. Increasingly, reps are factoring the lifestyle cost of early mornings, weekends, and on-call coverage into their compensation expectations. Companies that expect full OR presence without paying for it are watching reps leave for competitors who acknowledge what the job actually demands.

I don't have a clean number on how much "OR premium" reps expect. It varies too much by person and by market. But I'll say this: if you're hiring for a spine role that requires four days a week of OR coverage starting at 6am, and your comp package looks identical to a role that's mostly office-based selling, you're going to struggle.

Cardiovascular Has Caught Up

Cardiovascular device sales has seen the most compensation growth over the past two years, by my observation. I'm basing this on conversations with reps and hiring managers rather than a formal survey, so treat it as directional.

What's driving the comp increase is the expanding complexity of the role. A cardiovascular rep in 2026 isn't just selling established devices. They're managing reimbursement conversations with hospital administrators, supporting clinical education events, and providing technical case support for procedures like TAVR and leadless pacemaker implants. The skill set has expanded. Companies that haven't adjusted comp to reflect that are the ones losing people to the companies that have.

Surgical Robotics Is the Premium Segment

If you want to see the highest comp in medical device sales right now, look at surgical robotics. The premium exists because the job is hard. You're selling capital equipment that costs $1M-$3M per system. The sales cycle is 6-18 months. Your buyers are hospital C-suite executives, not surgeons (though the surgeons have significant influence). You need to be comfortable presenting ROI analyses to CFOs, navigating value analysis committees, and managing a complex multi-stakeholder process that feels more like enterprise software sales than traditional device sales.

The people who can do this well are genuinely scarce, which is why the comp is where it is.

Diagnostics: The Underrated Middle

Diagnostic device sales has historically been overshadowed by the sexier segments. But the compensation is respectable and the market is growing. The interesting thing about diagnostics is that the buyer is increasingly a laboratory director or hospital administrator rather than a physician. The conversation is about workflow efficiency, cost per test, turnaround time, and integration with the hospital's IT infrastructure.

I think diagnostics is underrated as a career path, and I realize I say that every time someone asks me about it, so maybe take it with appropriate skepticism. But the market is growing because of the expansion of AI-assisted diagnostics, point-of-care testing, and molecular diagnostics. Reps who get into this space now and develop expertise in one of those sub-segments are positioning themselves well. I know a diagnostics rep who turned down a cardiology device role last year because she thought the long-term trajectory in molecular diagnostics was better. Ask me in three years if she was right.

Geography and Comp: What the Data Shows

Title: Geography and Comp: What the Data Shows

Geography Matters More Than People Think

Texas is interesting and I think undervalued. Dallas, Houston, and Austin are large, high-volume markets with productive territories. I know reps who moved from New Jersey to Texas and describe it as a raise in real terms even though the nominal comp was similar.

The hardest territories to staff are the ones that combine moderate potential with low population appeal. Small cities in the Midwest, rural territories in the South and Mountain West. Companies often have to add $10K-$15K to their standard comp plan to attract anyone, and even then the positions can sit open for months. If you're a company with chronically unfilled rural territories, it might be worth considering contract coverage rather than leaving them empty.

Offer A vs. Offer B: Which Attracts Better Talent?

Title: Offer A vs. Offer B: Which Attracts Better Talent?

This is the second-most common comp mistake I see. Companies anchor on base salary and miss that top performers evaluate the upside, not the floor.

What Companies Get Wrong About Comp

Three patterns I see repeatedly.

Anchoring to last year's plan. The talent market moves. A comp plan that was competitive in 2024 might be 8-12% below market now. Companies that don't recalibrate annually lose candidates and wonder why.

Ignoring what competitors are offering. Before you make an offer, know what Stryker, Boston Scientific, Abbott, and whoever else is relevant in your segment are paying for comparable roles. If your offer isn't within 10% of the best alternative, the candidate will walk. The VP I quoted at the top lost someone over $13K. On an $840K territory, that $13K is noise. But it cost him his top candidate and probably four months of suboptimal territory performance while he started the search over.

Our medical sales compensation benchmarks can help you calibrate against the market. And if you're trying to figure out what the total cost comparison looks like between a permanent hire and a contract rep, the salary calculator models that out.

For the broader picture on where the device industry is headed and which companies are in the strongest position, our breakdown of the best medical device companies in 2026 covers it. And if you're looking at the market trends shaping device sales, the 2025 trends analysis is still relevant context for where 2026 is going.